Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Phase 4 Completed NCT04363697

Summary

This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.

Participants With the Composite Outcome of Cardiovascular Death or Worsening Heart Failure

2 months · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
• Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant — University of Utah
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• PROACTIVE-HF IDE Trial Heart Failure NYHA Class III — Endotronix, Inc.
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

All trials